NUCLEABIOMARKERS_____ PRESS RELEASE

Nuclea Biomarkers, LLC
105 South Street
Pittsfield, MA 01201
Phone 413-749-4705
Fax: 413-445-9930
Email: pr@nucleabiomarkers.com
www.nucleabiomarkers.com

FOR IMMEDIATE RELEASE

NUCLEA BIOMARKERS ESTABLISHES RESEARCH FELLOWSHIP IN THE LABORATORY OF DR. MASSIMO LODA OF DANA FARBER CANCER INSTITUTE

NUCLEA PROVIDES RESOURCES TO TRAIN A MEDICAL ONCOLOGY FELLOW

Pittsfield, Massachusetts …….. May 1, 2006 …….. Nuclea Biomarkers, LLC announced today that it has signed an agreement with Dana Farber Cancer Institute (DFCI) to establish a Research Fellowship in Medical Oncology in the Laboratory of Dr. Massimo Loda. Nuclea will provide the resources to train a Medical Oncology Fellow and further studies in Multi Spectral Imaging Techniques to identify certain genes and proteins that are involved in tumor formation, progression and metastasis.

Dr. Loda is a recognized expert in new biomarker antibody development and characterization. He is the Director of the Center for Molecular Oncologic Pathology and a Principle Investigator within the Lank Center for Genitourinary Oncology. The establishment of this fellowship will aid in the development of unique technologies to further progress the understanding of how tumors develop.

“We are very excited about the establishment of the first Nuclea Biomarkers DFCI Fellowship in Medical Oncology. We are proud to be associated with Dr. Loda’s research group and to provide resources to train a very talented fellow in the Medical Oncology field“ states Patrick Muraca, President and CEO. “The Medical Oncology Fellow will participate in the existing Nuclea and DFCI research collaboration”, Muraca states.

Nuclea Biomarkers, LLC - Nuclea Biomarkers, LLC is a biotechnology services company that has developed a novel technology platform to improve greatly the efficiency of drug discovery research. Using the Company's extensive libraries of genetic, molecular, and outcomes data and data-mining services, research professionals in pharmaceutical and life sciences companies are able to focus time and money on the most promising paths for diagnosing and treating a broad range of diseases.

Dana Farber Cancer Institute - The mission of Dana-Farber Cancer Institute is to provide expert, compassionate care to children and adults with cancer while advancing the understanding, diagnosis, treatment, cure, and prevention of cancer and related diseases.

Multi Spectral Imaging - Spectral imaging microscopy represents a technological advance over visual or RGB-camera-based analyses, providing images at multiple wavelengths and generating precise optical spectra at every pixel, and enabling applications in surgical pathology, multicolor fluorescence and immunohistochemistry. A variety of technologies are now available for use in combination with microscopy, including tunable filters, Fourier-transform interferometry, line-scanning prism or gratings-based devices, computed tomography, and others based on polarization effects. Mathematical approaches to these rich data sets may then be used to extract maximum possible information from the resulting data; this is an exciting and rapidly developing area of investigation.